Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115218) titled 'A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Newly diagnosed patients confirmed as myelodysplastic syndrome (MDS) with IB-1 or IB-2 according to the WHO-2022 classification
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-01
Target Sample Size: Treatment Group:28;
Countries of Recruitment:
China
To know more, visit ht...